Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm

AIDS

Volumn 27, Issue 5, 2013, Pages 731-737

  Nasrullah, Muazzam ^a   Wesolowski, Laura G ^a   Meyer III, William A ^b   Owen, S Michele ^a   Masciotra, Silvina ^a   Vorwald, Craig ^b   Becker, William J ^b   Branson, Bernard M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Fourth generation immunoassay; HIV testing algorithms; Specificity

Indexed keywords

VIRUS RNA;

ARTICLE; CLINICAL PROTOCOL; DIFFERENTIAL DIAGNOSIS; FALSE POSITIVE RESULT; HEALTH INSURANCE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; WESTERN BLOTTING;

ALGORITHMS; BLOTTING, WESTERN; DIAGNOSTIC TESTS, ROUTINE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOASSAY; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY;

EID: 84876412241     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835bc535     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep 1989; 38 (Suppl 7):1-7.
2. Centers for Disease Control Prevention. Acute HIV infection - New York City, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1296-1399.
3. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959.
4. Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004; 113:937-945.
5. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53:3611-3619.
6. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr 2010; 55 (2):102-105.
7. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011; 52 (Suppl 1):S17-S22.
8. Delaney KP, Heffelfinger JD, Wesolowski LG, Owen SM, Meyer WA 3rd, Kennedy S, et al. Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population. J Clin Virol 2011; 52 (Suppl 1):S5-S10.
9. Wesolowski LG, Delaney KP, Hart C, Dawson C, Owen SM, Candal D, et al. Performance of an alternative laboratory-based algorithm for diagnosis of HIV infection utilizing a third generation immunoassay, a rapid HIV-1/HIV-2 differentiation test and a DNA or RNA-based nucleic acid amplification test in persons with established HIV-1 infection and blood donors. J Clin Virol 2011; 52 (Suppl 1):S45-S49.
10. Nasrullah M, Ethridge SF, Delaney KP, Wesolowski LG, Granade TC, Schwendemann J, et al. Comparison of alternative interpretive criteria for the HIV-1 western blot and results of the Multispot HIV-1/HIV-2 rapid test for classifying HIV-1 and HIV-2 infections. J Clin Virol 2011; 52 (Suppl 1):S23-S27.
11. Kelly JA, Morin SF, Remien RH, Steward WT, Higgins JA, Seal DW, et al. Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. AIDS Behav 2009; 13:1068-1074.
12. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143:86-94.
13. Pandori MW, Hackett J Jr, Louie B, Vallari A, Dowling T, Liska S, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol 2009; 47:2639- 2642.
14. Chavez P, Wesolowski L, Patel P, Delaney K, Owen SM. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo assay. J Clin Virol 2011; 52 (Suppl 1):S51-S55.
15. Bentsen C, McLaughlin L, Mitchell E, Ferrera C, Liska S, Myers R, et al. Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groupsMand O) and HIV-2 in human serum or plasma. J Clin Virol 2011; 52 (Suppl 1):S57-S61.
16. Bio-Rad Laboratories. Product insert, GS HIV Combo Ag/Ab EIA, Bio-Rad, Redmond, WA, USA; 2011.
17. Stout RL, Fulks M, Dolan VF. Trends in mortality of insurance applicants with HIV infection. J Insur Med 2012; 43:67-75.
18. Bio-Rad Laboratories. Product insert, GS HIV-1/HIV-2 Plus O EIA, Bio-Rad, Redmond, WA, USA; 2005.
19. Bio-Rad Laboratories. Product insert, Multispot HIV-1/HIV-2 Rapid Test, Bio-Rad, Redmond, WA, USA; 2004.
20. Gen-Probe Incorporated. Product insert, APTIMA HIV-1 RNA Qualitative assay, Gen-Probe Incorporated, San Diego, CA, USA; 2006.
21. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871- 1879.
22. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 2007; 21:1625-1629.
23. Xiridou M, Geskus R, de Wit J, Coutinho R, Kretzschmar M. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS 2004; 18:1311-1320.
24. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med 2011; 364:1943-1954.
25. Wians FH Jr, Briscoe D, Anderson KM, Hicks PS, Smith DL, Clark TA, et al. Evaluation of four qualitative third-generation HIV antibody assays and the fourth-generation Abbott HIV Ag/Ab Combo test. Lab Med 2011; 42:523-535.
26. Centers for Disease Control and Prevention. HIV-2 Infection Surveillance - United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985-988.
27. Torian LV, Forgione LA, Punsalang AE, Pirillo RE, Oleszko WR. Comparison of Multispot EIA with western blot for confirmatory serodiagnosis of HIV. J Clin Virol 2011; 52 (Suppl 1):S41- S44.
28. Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588-1595.
29. Patel P, Mackellar D, Simmons P, Uniyal A, Gallagher K, Bennett B, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med 2010; 170:66-74.
30. AIDS info: clinical guidelines portal. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: baseline evaluation; 2012 [cited 24 April 2012]. http://aidsinfo.nih.gov/guidelines/html/ 1/adult-and-adolescent-treatmentguidelines/36/baseline-evaluation.
31. Ginocchio CC, Wang XP, Kaplan MH, Mulligan G, Witt D, Romano JW, et al. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol 1997; 35:2886-2893.
32. Claassen M, van Zyl GU, Preiser W. Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ system. J Virol Methods 2008; 150:80-81.
33. Valentine-Thon E. Quality control in nucleic acid testing: where do we stand? J Clin Virol 2002; 25 (Suppl 3):S13-S21.